RxDoctor Payments Data

Barbara Bowers, NP

Adult Health · Indianapolis, INNPI 1407851033

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,987in general payments, 2019–2025

Across 351 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$579
  • Biogen$559
  • Lilly USA, LLC$426
  • Neurocrine Biosciences, Inc.$365
  • Jazz Pharmaceuticals Inc.$362
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,987 in reported general payments places this provider in the 90th percentile of 391 adult health providers in Indiana.

See all adult health providers in Indiana

Medicare billing

Part B allowed, 2024
$9,793
Medicare patients
75
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant18$24,162
Lacosamide18$2,487
Levetiracetam76$1,883
Donepezil Hcl26$859
Tizanidine Hcl14$833
Gabapentin77$828
Propranolol Hcl ErPropranolol Hcl18$802
Primidone18$783
Pregabalin31$729
Divalproex Sodium24$588
Memantine Hcl17$525
Amitriptyline Hcl40$399
ClopidogrelClopidogrel Bisulfate26$359
Duloxetine Hcl12$332
Lamotrigine24$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta$1,219$24,16218 claims
Upsher-smith Laboratories LLCTopiramate$18$28319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 adult health providers in Indiana.

Other adult health in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →